Dimensional Fund Advisors LP raised its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 60.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 215,265 shares of the company's stock after purchasing an additional 80,905 shares during the quarter. Dimensional Fund Advisors LP owned 0.38% of Design Therapeutics worth $1,328,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of DSGN. Invesco Ltd. bought a new stake in Design Therapeutics during the 4th quarter valued at approximately $71,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Design Therapeutics during the fourth quarter worth $74,000. Kennedy Capital Management LLC purchased a new position in Design Therapeutics during the fourth quarter valued at $88,000. Intech Investment Management LLC bought a new stake in Design Therapeutics in the 4th quarter valued at $109,000. Finally, Wells Fargo & Company MN lifted its stake in Design Therapeutics by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 18,428 shares of the company's stock worth $114,000 after purchasing an additional 4,013 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.
Design Therapeutics Stock Down 1.9%
Shares of Design Therapeutics stock opened at $3.60 on Thursday. The firm has a market cap of $204.37 million, a price-to-earnings ratio of -4.24 and a beta of 1.77. Design Therapeutics, Inc. has a twelve month low of $2.60 and a twelve month high of $7.77. The business has a 50-day moving average price of $3.81 and a 200-day moving average price of $4.85.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.03). On average, equities analysts expect that Design Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.
Design Therapeutics Profile
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
See Also
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
